Business
Globus Medical Reports First Quarter 2025 Results
AUDUBON, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025. Worldwide net sales were $598.1 million, a decrease of 1.4%, or a decrease of 0.8% on a constant currency basisGAAP net income for the quarter was $75.5 millionGAAP diluted earnings per share (“EPS”) was $0.54 and non-GAAP diluted EPS was $0.68 “Our first quarter results were impacted by softer E
About this update from Globus Medical, Inc.
[{"type":"image","alt":"Globus Medical","displaySize":"","headline":null,"caption":"Globus Medical","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":236,"url":"https://media.zenfs.com/en/globenewswire.com/00da90d72bee150b4be4104613ae2ce4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HbC9jzNGkCK8ASuuAaxfXw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMzMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/00da90d72bee150b4be4104613ae2ce4","width":300,"height":236}},"lazy":false},{"type":"text","content":"AUDUBON, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025.","length":207,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Worldwide net sales were $598.1 million, a decrease of 1.4%, or a decrease of 0.8% on a constant currency basis","length":111,"tagName":"p"}]},{"val":[{"type":"text","content":"GAAP net income for the quarter was $75.5 million","length":49,"tagName":"p"}]},{"val":[{"type":"text","content":"GAAP diluted earnings per share (“EPS”) was $0.54 and non-GAAP diluted EPS was $0.68","length":84,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":244,"olType":false},{"type":"text","content":"“Our first quarter results were impacted by softer Enabling Technology deal closures, temporary integration related supply chain disruption, and timing of international distributor orders, partially offset by strength in our core US spine business,” commented Dan Scavilla, President and Chief Executive Officer. “We are encouraged by the continued strong performance in April across these businesses and remain confident in our ability to drive above-market revenue growth as we move forward. We will continue to invest and provide innovative and clinically advanced products and solutions that help our surgeons improve patient care. We remain steadfast in our vision for the future.”","length":698,"tagName":"p"},{"type":"text","content":"“We remain focused on our strategy and continue to execute against those objectives,” commented Keith Pfeil, COO-CFO. “During the quarter, we returned to a debt-free status, as we paid off the remaining $450 million of debt assumed from the NuVasive merger. We delivered record Q1 free cash f...